Detalhe da pesquisa
1.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Am J Hematol
; 98(2): 272-281, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309981
2.
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Hematol Oncol
; 40(2): 269-279, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35043428
3.
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Jpn J Clin Oncol
; 52(1): 29-38, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739075
4.
Glecaprevir/pibrentasvir for 8â¯weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
J Hepatol
; 72(3): 441-449, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682879
5.
Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.
Eur J Clin Pharmacol
; 75(2): 207-216, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291369
6.
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
J Infect Dis
; 217(3): 474-482, 2018 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29228392
7.
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.
J Pharmacokinet Pharmacodyn
; 45(3): 443-456, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29427135
8.
Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
Antimicrob Agents Chemother
; 61(2)2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27919899
9.
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Am J Hematol
; 97(11): E416-E419, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054316
10.
Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Antimicrob Agents Chemother
; 60(1): 105-14, 2016 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26459906
11.
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
J Hepatol
; 63(1): 20-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25646891
12.
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
N Engl J Med
; 363(21): 1991-2003, 2010 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21083385
13.
Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
J Clin Pharmacol
; 63(1): 119-125, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996877
14.
Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects.
Pharmacol Res Perspect
; 10(6): e01024, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36416673
15.
Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality.
Clin Transl Sci
; 15(12): 2785-2795, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36129129
16.
Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro.
Drug Metab Dispos
; 38(2): 249-59, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19889885
17.
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
Adv Ther
; 37(7): 3299-3310, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32451952
18.
Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Eur J Drug Metab Pharmacokinet
; 44(1): 43-52, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909549
19.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.
Kidney Int Rep
; 4(2): 257-266, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30775622
20.
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.
Clin Pharmacokinet
; 57(11): 1407-1419, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29516428